Cancer development and its response to therapy are regulated by inflammation, which
either promotes or suppresses tumor progression, potentially displaying opposing effects on …

Much progress has been made in targeting CD47 for cancer immunotherapy in solid tumors
(ST) and hematological malignancies. We summarized the CD47-related clinical research …

Progressive multiple sclerosis (MS) is characterized by unrelenting neurodegeneration,
which causes cumulative disability and is refractory to current treatments. Drug development …

Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities
has become a promising strategy in clinical management of hematologic malignancies. The …

The programmed cell death protein 1 (PD-1) pathway has received considerable attention
due to its role in eliciting the immune checkpoint response of T cells, resulting in tumor cells …

CD47 is an immunoglobulin that is overexpressed on the surface of many types of cancer
cells. CD47 forms a signaling complex with signal-regulatory protein α (SIRPα), enabling the …

Rational design of tumor microenvironment (TME)‐activated nanocomposites provides an
innovative strategy to construct responsive oncotherapy. In colorectal cancer (CRC), the …

Tissue macrophages rapidly recognize and engulf apoptotic cells. These events require the
display of so-called eat-me signals on the apoptotic cell surface, the most fundamental of …

WNT/β-catenin signaling is involved in many physiological processes. Its implication in
embryonic development, cell migration, and polarization has been shown. Nevertheless …

The term 'immunogenic cell death'(ICD) denotes an immunologically unique type of
regulated cell death that enables, rather than suppresses, T cell-driven immune responses …